Literature DB >> 30714527

Small Molecule Natural Products and Alzheimer's Disease.

Xiaoai Wu1, Huawei Cai1, Lili Pan1, Gang Cui2, Feng Qin1, YunChun Li1, Zhengxin Cai3.   

Abstract

Alzheimer's disease (AD) is a progressive and deadly neurodegenerative disease that is characterized by memory loss, cognitive impairment and dementia. Several hypotheses have been proposed for the pathogenesis based on the pathological changes in the brain of AD patients during the last few decades. Unfortunately, there is no effective agents/therapies to prevent or control AD at present. Currently, only a few drugs, which function as acetylcholinesterase (AChE) inhibitors or N-methyl-Daspartate (NMDA) receptor antagonists, are available to alleviate symptoms. Since many small molecule natural products have shown their functions as agonists or antagonists of receptors, as well as inhibitors of enzymes and proteins in the brain during the development of central nervous system (CNS) drugs, it is likely that natural products will play an important role in anti-AD drug development. We review recent papers on using small molecule natural products as drug candidates for the treatment of AD. These natural products possess antioxidant, anti-inflammatory, anticholinesterase, anti-amyloidogenic and neuroprotective activities. Moreover, bioactive natural products intended to be used for preventing AD, reducing the symptoms of AD and the new targets for treatment of AD are summarized. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Acetylcholinesterase inhibitors; Alzheimer's disease; Anti-inflammatory; Antioxidants; Neurofibrillary; Neuroprotective.

Mesh:

Substances:

Year:  2019        PMID: 30714527     DOI: 10.2174/1568026619666190201153257

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  4 in total

1.  MiR-191-5p alleviates microglial cell injury by targeting Map3k12 (mitogen-activated protein kinase kinase kinase 12) to inhibit the MAPK (mitogen-activated protein kinase) signaling pathway in Alzheimer's disease.

Authors:  Wenjun Wan; Ganzhe Liu; Xia Li; Yu Liu; Ying Wang; Haisong Pan; Jun Hu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

2.  Baicalin Attenuated Aβ 1-42-Induced Apoptosis in SH-SY5Y Cells by Inhibiting the Ras-ERK Signaling Pathway.

Authors:  Zhenyan Song; Chunxiang He; Wenjing Yu; Miao Yang; Ze Li; Ping Li; Xu Zhu; Chen Xiao; Shaowu Cheng
Journal:  Biomed Res Int       Date:  2022-04-27       Impact factor: 3.246

Review 3.  Oligomeropathies, inflammation and prion protein binding.

Authors:  Gianluigi Forloni; Pietro La Vitola; Claudia Balducci
Journal:  Front Neurosci       Date:  2022-08-23       Impact factor: 5.152

Review 4.  Mitochondrial Dysfunction and Alpha-Lipoic Acid: Beneficial or Harmful in Alzheimer's Disease?

Authors:  Sávio Monteiro Dos Santos; Camila Fernanda Rodrigues Romeiro; Caroline Azulay Rodrigues; Alícia Renata Lima Cerqueira; Marta Chagas Monteiro
Journal:  Oxid Med Cell Longev       Date:  2019-11-30       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.